Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023)

Historic Cash from Financing Activities for Spero Therapeutics (SPRO) over the last 8 years, with Q4 2023 value amounting to $1000.0.

  • Spero Therapeutics' Cash from Financing Activities fell 9999.29% to $1000.0 in Q4 2023 from the same period last year, while for Dec 2024 it was $221000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $221000.0 for FY2023, which is 10074.78% up from last year.
  • Latest data reveals that Spero Therapeutics reported Cash from Financing Activities of $1000.0 as of Q4 2023, which was down 9999.29% from $220000.0 recorded in Q3 2023.
  • Spero Therapeutics' Cash from Financing Activities' 5-year high stood at $77.2 million during Q3 2020, with a 5-year trough of -$53.7 million in Q2 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $5.9 million (2019), whereas its average is $11.2 million.
  • Per our database at Business Quant, Spero Therapeutics' Cash from Financing Activities surged by 77205000.0% in 2020 and then crashed by 3205059.52% in 2022.
  • Over the past 5 years, Spero Therapeutics' Cash from Financing Activities (Quarter) stood at $5.6 million in 2019, then soared by 187.37% to $16.1 million in 2020, then skyrocketed by 212.92% to $50.3 million in 2021, then crashed by 71.84% to $14.2 million in 2022, then crashed by 99.99% to $1000.0 in 2023.
  • Its Cash from Financing Activities stands at $1000.0 for Q4 2023, versus $220000.0 for Q3 2023 and $14.2 million for Q4 2022.